RecruitingPhase 2NCT06138275

Elranatamab in R/R Multiple Myeloma

A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma

Sponsor

Massachusetts General Hospital

Enrollment

32 participants

Start Date

Mar 8, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma Refractory Multiple Myeloma Relapse Multiple Myeloma

Summary

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing elranatamab, a type of immunotherapy called a bispecific antibody, for people with relapsed or refractory multiple myeloma — a blood cancer in the bone marrow that has come back or stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have multiple myeloma that has relapsed (come back) or is refractory (not responding) to prior therapy - Your overall health is good (ECOG performance status 0 or 1) - You are willing to use contraception if you are of childbearing potential - You meet blood count and organ function requirements **You may NOT be eligible if...** - You have not previously been treated for multiple myeloma - You are pregnant or breastfeeding - You have health conditions that make you unable to tolerate the drug - You do not meet the required performance status or organ function levels Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.